30-Month Stay: How Patent Litigation Delays Generic Drug Approval

When a brand-name drug hits the market, it’s protected by patents that give the maker exclusive rights to sell it-often for 20 years. But here’s the catch: those patents don’t always line up with when the drug actually gets approved by the FDA. That’s where the 30-month stay comes in. It’s not a law passed yesterday. It’s been around since 1984, part of the Hatch-Waxman Act, and it’s still shaping who gets to sell cheap generic versions of drugs-and when.

What Exactly Is the 30-Month Stay?

The 30-month stay is a legal pause button. When a generic drug company files an application with the FDA to sell a cheaper version of a brand-name drug, they have to say whether they believe the patents on that drug are invalid or won’t be infringed. That’s called a Paragraph IV certification. If the brand-name company doesn’t like that claim, they can sue for patent infringement. Once they do, the FDA is legally blocked from giving final approval to the generic drug for up to 30 months.

This isn’t a delay in review. The FDA still reads the application, checks the science, runs the tests. They can even give what’s called a “tentative approval”-meaning the generic is ready to go, legally and scientifically. But they can’t let it hit shelves until the 30 months are up, or the court rules in favor of the generic maker.

Why Does This System Exist?

The Hatch-Waxman Act was meant to strike a balance. On one side, you want generic drugs to come to market fast-cheaper meds mean lower costs for patients and insurers. On the other, you need to protect the companies that spent billions developing the original drug. Without patent protection, no one would invest in new medicines.

The 30-month stay was designed to give brand companies enough time to resolve patent disputes without completely shutting down generic competition. It’s not supposed to be a permanent wall. It’s a clock. But in practice, that clock often runs longer than intended.

How Long Does It Really Last?

The name says 30 months. But that’s not always the end of the story. If the lawsuit isn’t settled by then, the FDA can keep the stay going until the court makes a final decision. Courts can also shorten it if they find the lawsuit was filed just to delay competition.

And here’s where things get messy. If the brand drug also has a five-year exclusivity period because it’s a new chemical entity, the total delay can stretch to nearly 40 months. That’s because the exclusivity period kicks in first, and the 30-month stay runs on top of it.

Even after the stay ends, the generic doesn’t always launch right away. FDA data shows there’s usually a 3.2-year gap between when the stay expires and when the generic actually hits pharmacies. Why? Because the generic company might need time to ramp up production, negotiate with insurers, or deal with other legal hurdles.

Who’s Playing the Game?

The first generic company to file a successful Paragraph IV challenge gets a huge reward: 180 days of exclusive sales. No other generic can enter during that time. That’s why multiple companies often race to be first. In 2022, 72% of drugs facing generic challenges had more than one company filing a Paragraph IV notice. And drugs with multiple challengers got to market 8.2 months faster on average than those with just one.

But this race isn’t cheap. A 2022 survey of generic manufacturers found that 63% spent between $3 million and $5 million per drug just on patent litigation. That’s money that doesn’t go toward making the drug-it goes toward lawyers, court filings, and expert witnesses.

Brand companies aren’t sitting still either. They’ve learned to list more patents in the FDA’s Orange Book-the official list of protected drugs. In 1995, the average drug had 1.2 patents listed. By 2022, that number had jumped to 8.3. Many of these are secondary patents-on things like pill coatings, dosing schedules, or delivery methods-not the core invention. A 2019 Brookings study found that 67% of patents listed for top-selling drugs were filed after the original approval. These aren’t breakthroughs. They’re legal maneuvers.

Is This System Working?

The numbers tell a split story. On one hand, since 1984, over 14,000 generic drugs have been approved. That’s saved U.S. consumers more than $2.2 trillion, according to former FDA Commissioner Scott Gottlieb. Generic drugs now make up 90% of all prescriptions but only 23% of total drug spending.

On the other hand, the FTC found that 78% of patent lawsuits involving generics ended in settlements that delayed generic entry beyond the patent’s expiration date. That’s called a “pay-for-delay” deal-where the brand company pays the generic maker to stay off the market. While courts have cracked down on these, they still happen.

And the cost? The FTC estimates patent litigation delays add $13.9 billion to U.S. drug costs every year. That’s not just about the drug price. It’s about delayed access. A cancer patient waiting for a cheaper version of their treatment. A diabetic paying hundreds more because the generic hasn’t launched yet.

What’s Changing?

There’s growing pressure to fix the system. In 2023, Congress introduced the Affordable Prescriptions for Patients Act, which would cut the 30-month stay down to 18 months and ban stays for secondary patents. The FDA also proposed new rules to make patent listings in the Orange Book more transparent-forcing companies to prove each patent actually covers the drug.

The biologics market is shifting too. Drugs like insulin and cancer treatments are increasingly biologics, which are made from living cells, not chemicals. They fall under a different law-the BPCIA-which gives them 12 years of exclusivity but doesn’t have a 30-month stay. So while small-molecule drugs are stuck in legal limbo, biologics are moving toward faster generic competition.

What Does This Mean for Patients?

If you’re taking a brand-name drug and wondering when a cheaper version will arrive, the answer isn’t just “when the patent expires.” It’s “when the lawsuits end.” Even if the patent runs out in 2026, the generic might not hit shelves until 2028-or later-if the brand company files multiple lawsuits or settles with the first challenger.

The system is designed to protect innovation. But too often, it’s being used to protect profits. The 30-month stay was never meant to be a tool for endless delay. Yet today, it’s one of the biggest reasons why patients wait years for affordable medicines.

What’s Next?

The next five years will decide whether the 30-month stay stays as it is-or gets rewritten. With bipartisan support for reform and over $78 billion worth of brand drugs set to lose patent protection by 2028, the pressure is on. If the system changes, patients could see generic drugs arrive months, even years, sooner.

Until then, the clock keeps ticking. And for many, every month counts.